Skip to main content
. 2020 Apr 14;2020:5759265. doi: 10.1155/2020/5759265

Table 4.

Administration of co-analgesics and adjuvants.

Immediately prior to tapentadol treatment At the start of tapentadol treatment At the end of observation
Patients aged >65 years (n = 752)
 Co-analgesics 299 (39.8%) 275 (36.6%) 249 (33.1%)
  Antidepressants 229 (30.5%) 219 (29.1%) 205 (27.3%)
  Antiepileptics 121 (16.1%) 97 (12.9%) 79 (10.5%)
  No data 0 0 30 (4%)
 Adjuvants 221 (29.4%) 197 (26.2%) 152 (20.2%)
  Antiemetics 83 (11%) 70 (9.3%) 49 (6.5%)
  Laxatives 170 (22.6%) 144 (19.2%) 120 (16%)
  Adjuvants NOS 1 (0.1%) 2 (0.3%) 0
  No data 3 (0.4%) 3 (0.4%) 38 (5.1%)
 Rescue medication 256 (34%) 235 (31.3%) 212 (28.2%)
  No data 4 (0.5%) 2 (0.3%) 39 (5.2%)
Patients aged ≤65 years (n = 282)
 Co-analgesics 133 (47.2%) 110 (39%) 92 (32.6%)
  Antidepressants 111 (39.4%) 99 (35.1%) 81 (28.7%)
  Antiepileptics 54 (19.2%) 36 (12.8%) 30 (10.6%)
  No data 0 0 8 (2.8%)
 Adjuvants 67 (23.8%) 53 (18.8%) 28 (9.9%)
  Antiemetics 36 (12.8%) 28 (9.9%) 15 (5.3%)
  Laxatives 45 (16%) 33 (11.7%) 20 (7.1%)
  Adjuvants NOS 1 (0.4%) 1 (0.4%) 0
  No data 1 (0.4%) 2 (0.7%) 13 (4.6%)
 Rescue medication 76 (27%) 74 (26.2%) 70 (24.8%)
  No data 2 (0.6%) 1 (0.4%) 10 (3.6%)

NOS, not otherwise specified. Data are number of patients (%).